Search - tctmd.com

Displaying 121 - 140 of 3616

Sort: Relevancy | Date

Presentation TCT 2016

A Prospective, Randomized Trial of Impella vs Intra-aortic Balloon Counterpulsation in Patients with Cardiogenic Shock

Presenter: Thomas F. Luscher, Patrick W. Serruys, Jose P.S. Henriques

October 31, 2016

Presentation TCT 2016

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

Presenter: Sorin J. Brener, Jean-François Tanguay, Jaya Chandrasekhar

October 31, 2016

Presentation TCT 2016

GRACIA-4 (and Pooled Analysis): A Prospective, Randomized Trial of Percutaneous Coronary Intervention in Patients with STEMI with and without Preceding Fibrinolytic Therapy

Presenter: Thomas F. Luscher, Patrick W. Serruys, Francisco Fdez-Aviles

October 31, 2016

Presentation TCT 2016

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Li Zhi

October 31, 2016

Presentation TCT 2016

EXPLORE: Left Ventricular Function Recovery from a Prospective, Randomized Trial of CTO Intervention after Primary PCI in Patients with STEMI

Presenter: Joseph A. Hill, Steven P. Marso, Jose P.S. Henriques

October 31, 2016

News Industry News

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

October 31, 2016

Presentation TCT 2016

OPINION: OCT Follow-Up Substudy from a Randomized Trial of OFDI-Guided PCI vs. IVUS-Guided PCI

Presenter: Joseph A. Hill, Steven P. Marso, Hiromasa Otake

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Industry News

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

October 31, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

Presenter: Scott Berry, Stuart J. Pocock, Ajay J. Kirtane

October 30, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Mediation Analysis: A Method to Assign Attributable Risk

Presenter: Scott Berry, Stuart J. Pocock, Bjorn Redfors

October 30, 2016

Presentation TCT 2016

Surrogate Endpoints: Construction, Validation, and Trustiness

Presenter: Scott Berry, Stuart J. Pocock, William S. Weintraub

October 30, 2016

Presentation TCT 2016

Accounting for the Risk of Competing Events

Presenter: Scott Berry, Stuart J. Pocock, Peter Juni

October 30, 2016

Advertisement

A Prospective, Randomized Trial of Impella vs Intra-aortic Balloon Counterpulsation in Patients with Cardiogenic Shock

TCT 65: Comparative Efficacy and Safety of Coronary Stents in Diabetic Patients With and Without Insulin Treatment: A Pooled Patient Level Analysis From 17 Randomized Trials

GRACIA-4 (and Pooled Analysis): A Prospective, Randomized Trial of Percutaneous Coronary Intervention in Patients with STEMI with and without Preceding Fibrinolytic Therapy

TCT 69: A Randomized Comparison of the Second Generation Biodegradable Polymer Sirolimus-Eluting Stent (EXCEL-II) and the First Generation EXCEL-I Stent in Patients With De Novo Coronary Lesions: Clinical and Angiographic Outcomes of the CREDIT II Trial

EXPLORE: Left Ventricular Function Recovery from a Prospective, Randomized Trial of CTO Intervention after Primary PCI in Patients with STEMI

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

OPINION: OCT Follow-Up Substudy from a Randomized Trial of OFDI-Guided PCI vs. IVUS-Guided PCI

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Key Contributions to TAVR Clinical Research VI: Updates From the NOTION Randomized All-Comers Trial

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Mediation Analysis: A Method to Assign Attributable Risk

Surrogate Endpoints: Construction, Validation, and Trustiness

Accounting for the Risk of Competing Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content